We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-6.18%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$20.6B
AUM Growth
-$2.22B
Cap. Flow
+$62.6M
Cap. Flow %
0.3%
Top 10 Hldgs %
83.49%
Holding
126
New
5
Increased
17
Reduced
8
Closed
5

Top Buys

Rank Stock Value
1
TRDA icon
Entrada Therapeutics
TRDA
+$114M
2
INCY icon
Incyte
INCY
+$108M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$46.7M
4
TSVT
2seventy bio
TSVT
+$26M
5
TVTX icon
Travere Therapeutics
TVTX
+$17.7M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$66.1M
2
FLGT icon
Fulgent Genetics
FLGT
+$17.5M
3
BLUE
bluebird bio
BLUE
+$16M
4
MIRM icon
Mirum Pharmaceuticals
MIRM
+$12.9M
5
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$11.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.19%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
$7.25B 35.27%
46,893,364
-394,895
-0.8% -$66.1M
ONC
2
BeOne Medicines Ltd
ONC
$34.2B
$3.16B 15.38%
11,668,897
– –
INCY icon
3
Incyte
INCY
$25.5B
$2.47B 12.01%
33,618,063
+1,595,938
+5% +$108M
KOD icon
4
Kodiak Sciences
KOD
$2.59B
$1.24B 6.06%
14,681,304
– –
ACAD icon
5
Acadia Pharmaceuticals
ACAD
$4.52B
$978M 4.76%
41,910,704
– –
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$11.9B
$673M 3.28%
7,620,494
– –
ASND icon
7
Ascendis Pharma A/S
ASND
$16.7B
$611M 2.97%
4,541,604
– –
ARGX icon
8
argenx
ARGX
$55.3B
$392M 1.91%
1,119,557
– –
MRTX
9
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$207M 1.01%
1,409,784
– –
BCRX icon
10
BioCryst Pharmaceuticals
BCRX
$2.47B
$176M 0.86%
12,710,818
– –
KYMR icon
11
Kymera Therapeutics
KYMR
$8.88B
$151M 0.74%
2,384,742
– –
NVTA
12
DELISTED
Invitae Corporation
NVTA
$151M 0.73%
9,873,488
– –
ABCL icon
13
AbCellera Biologics
ABCL
$1.69B
$149M 0.73%
10,450,180
– –
MDGL icon
14
Madrigal Pharmaceuticals
MDGL
$12.6B
$127M 0.62%
1,499,213
– –
PRLD icon
15
Prelude Therapeutics
PRLD
$385M
$126M 0.61%
10,123,824
– –
LEGN icon
16
Legend Biotech
LEGN
$3.68B
$116M 0.56%
2,489,003
+125,000
+5% +$6.34M
PACB icon
17
Pacific Biosciences
PACB
$450M
$111M 0.54%
5,444,963
– –
GBT
18
DELISTED
Global Blood Therapeutics, Inc.
GBT
$97M 0.47%
3,314,765
+97,324
+3% +$3.01M
CERS icon
19
Cerus
CERS
$585M
$93.4M 0.45%
13,713,195
– –
IGMS
20
DELISTED
IGM Biosciences
IGMS
$92.6M 0.45%
3,156,102
– –
IMCR icon
21
Immunocore
IMCR
$1.71B
$86.3M 0.42%
2,520,730
– –
TVTX icon
22
Travere Therapeutics
TVTX
$5.34B
$82.8M 0.4%
2,669,054
+629,282
+31% +$17.7M
TRDA icon
23
Entrada Therapeutics
TRDA
$260M
$80.5M 0.39%
+4,704,419
New +$114M
HRTX icon
24
Heron Therapeutics
HRTX
$95.6M
$74.2M 0.36%
8,131,678
– –
AMRN
25
Amarin Corp
AMRN
$298M
$71.3M 0.35%
1,058,490
-34,312
-3% -$2.84M
1
2 3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2021 Portfolio in Review

As of Q4 2021, Baker Bros. Advisors held 126 positions worth $20.6B, down 9.7% from $22.8B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Baker Bros. Advisors's Q4 2021 filing shows 5 new, 17 increased, 8 reduced and 5 closed positions. Its largest new stake was Entrada Therapeutics: 4,704,419 shares worth $80.5M. The largest sale was Seagen Inc. Common Stock, an estimated $66.1M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q4 2021 buy was Entrada Therapeutics: 4,704,419 shares worth $80.5M.
  • Baker Bros. Advisors added most to Incyte in Q4 2021, an estimated $108M increase.
  • Baker Bros. Advisors's biggest Q4 2021 reduction was Seagen Inc. Common Stock, cutting an estimated $66.1M.
  • Baker Bros. Advisors fully exited Mirum Pharmaceuticals in Q4 2021, selling an estimated $12.9M.
  • Baker Bros. Advisors's ten largest holdings make up 83% of its $20.6B portfolio in Q4 2021.
  • Baker Bros. Advisors opened 5 new positions and closed 5 in Q4 2021.
  • Baker Bros. Advisors's portfolio value fell 9.7% quarter-over-quarter to $20.6B.

Based on Baker Bros. Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.